214 related articles for article (PubMed ID: 24353168)
1. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.
Hsu JW; Yin PN; Wood R; Messing J; Messing E; Lee YF
Oncotarget; 2013 Dec; 4(12):2397-406. PubMed ID: 24353168
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.
Tan QL; Zhou CY; Cheng L; Luo M; Liu CP; Xu WX; Zhang X; Zeng X
Mol Med Rep; 2020 Jul; 22(1):362-370. PubMed ID: 32319653
[TBL] [Abstract][Full Text] [Related]
3. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
4. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
5. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.
Dovedi SJ; Kirby JA; Atkins H; Davies BR; Kelly JD
J Urol; 2005 Jul; 174(1):332-7; discussion 337. PubMed ID: 15947685
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
8. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.
Bevers RF; Kurth KH; Schamhart DH
Br J Cancer; 2004 Aug; 91(4):607-12. PubMed ID: 15266312
[TBL] [Abstract][Full Text] [Related]
9. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.
Shang Z; Li Y; Hsu I; Zhang M; Tian J; Wen S; Han R; Messing EM; Chang C; Niu Y; Yeh S
Oncotarget; 2016 May; 7(19):27325-35. PubMed ID: 27092883
[TBL] [Abstract][Full Text] [Related]
10. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
11. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
Luo Y; Han R; Evanoff DP; Chen X
Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
[TBL] [Abstract][Full Text] [Related]
14. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
16. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
18. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
